81 related articles for article (PubMed ID: 34478210)
1. Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma: Retrospective real-life data.
Gürbüz M; Doğan İ; Akkuş E; Ermiş H; Utkan G; Vatansever S; Taş F
Dermatol Ther; 2021 Nov; 34(6):e15122. PubMed ID: 34478210
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial.
Ben Ishai M; Tiosano A; Fenig E; Ben Simon G; Yassur I
JAMA Ophthalmol; 2020 Jul; 138(7):749-755. PubMed ID: 32407451
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.
Lear JT; Migden MR; Lewis KD; Chang ALS; Guminski A; Gutzmer R; Dirix L; Combemale P; Stratigos A; Plummer R; Castro H; Yi T; Mone M; Zhou J; Trefzer U; Kaatz M; Loquai C; Kudchadkar R; Sellami D; Dummer R
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):372-381. PubMed ID: 28846163
[TBL] [Abstract][Full Text] [Related]
4. Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness.
Mannino M; Piccerillo A; Fabbrocini G; Quaglino P; Argenziano G; Dika E; Ascierto PA; Pellacani G; Longo C; Fargnoli MC; Bianchi L; Calzavara-Pinton P; Zalaudek I; Fava P; Scalvenzi M; Bocchino E; Di Stefani A; Peris K;
Dermatology; 2023; 239(6):868-876. PubMed ID: 37311439
[TBL] [Abstract][Full Text] [Related]
5. Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma.
Lavasidis G; Tzamalis A; Tsinopoulos I; Ziakas N
Cancer Treat Res Commun; 2024; 39():100796. PubMed ID: 38367414
[TBL] [Abstract][Full Text] [Related]
6. Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review.
Patel S; Armbruster H; Pardo G; Archambeau B; Kim NH; Jeter J; Wu R; Kendra K; Contreras CM; Spaccarelli N; Dulmage B; Pootrakul L; Carr DR; Verschraegen C
PLoS One; 2024; 19(4):e0297531. PubMed ID: 38687774
[TBL] [Abstract][Full Text] [Related]
7. Review of Targeted Therapy, Vismodegib, for the Treatment of Periocular Basal Cell Carcinoma.
Singalavanija T; Ceylanoglu KS; Juntipwong S; Beser BG; Elner VM; Worden FP; Demirci H
Ophthalmic Plast Reconstr Surg; 2024 Jan-Feb 01; 40(1):1-10. PubMed ID: 37552493
[TBL] [Abstract][Full Text] [Related]
8. Clinical determinants of clinical response to Sonidegib in advanced basal cell carcinoma: a monocenter experience.
Spallone G; Carbone A; Sperati F; Frascione P; Eibenschutz L
Eur Rev Med Pharmacol Sci; 2024 Apr; 28(7):2923-2928. PubMed ID: 38639529
[TBL] [Abstract][Full Text] [Related]
9. Real-Life Effectiveness of Vismodegib in Patients with Metastatic and Advanced Basal Cell Carcinoma: Characterization of Adverse Events and Assessment of Health-Related Quality of Life using the Dermatology Life Quality Index (DLQI) Test.
Villani A; Fabbrocini G; Cappello M; Costa C; Scalvenzi M
Dermatol Ther (Heidelb); 2019 Sep; 9(3):505-510. PubMed ID: 31165365
[TBL] [Abstract][Full Text] [Related]
10. Real-World Experience with Vismodegib on Advanced and Multiple BCCs: Data from the RELIVIS Study.
Ruiz-Salas V; Podlipnik S; Sandoval-Clavijo A; Sanmartin-Jiménez O; Bernia-Petit E; Bonfill-Ortí M; Bassas-Freixas P; Yebenes-Marsal M; Flórez-Menéndez Á; Solá-Ortigosa J; Just-Sarobé M; Aguayo-Ortiz R; Masferrer I Niubó E; Quintana-Codina M; Deza G; Jaka A; Fuentes MJ; Cañueto J; Toll A
Dermatology; 2023; 239(5):685-693. PubMed ID: 37257423
[TBL] [Abstract][Full Text] [Related]
11. Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity.
Scalvenzi M; Cappello M; Costa C; Fabbrocini G; Luciano M; Villani A
Dermatol Ther (Heidelb); 2020 Jun; 10(3):465-468. PubMed ID: 32240528
[TBL] [Abstract][Full Text] [Related]
12. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma.
Bertrand N; Guerreschi P; Basset-Seguin N; Saiag P; Dupuy A; Dalac-Rat S; Dziwniel V; Depoortère C; Duhamel A; Mortier L
EClinicalMedicine; 2021 May; 35():100844. PubMed ID: 33997740
[TBL] [Abstract][Full Text] [Related]
13. The initial rate of tumour response to vismodegib treatment, can predict a complete response outcome for periocular LA-BCC.
Tiosano A; Ben-Ishai M; Fenig E; Ben Simon GJ; Yassur I
Eye (Lond); 2023 Feb; 37(3):531-536. PubMed ID: 35210571
[TBL] [Abstract][Full Text] [Related]
14. Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma.
Barker CA; Dufault S; Arron ST; Ho AL; Algazi AP; Dunn LA; Humphries AA; Hultman C; Lian M; Knott PD; Yom SS
J Clin Oncol; 2024 Apr; ():JCO2301708. PubMed ID: 38630954
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Histopathologic Characteristics of Metastatic and Locally Advanced Cutaneous Basal Cell Carcinomas.
Baker LX; Grilletta E; Zwerner JP; Boyd AS; Wheless L
Am J Dermatopathol; 2021 Dec; 43(12):e169-e174. PubMed ID: 34001746
[TBL] [Abstract][Full Text] [Related]
16. Spotlight on vismodegib in the treatment of basal cell carcinoma: an evidence-based review of its place in therapy.
Apalla Z; Papageorgiou C; Lallas A; Sotiriou E; Lazaridou E; Vakirlis E; Kyrgidis A; Ioannides D
Clin Cosmet Investig Dermatol; 2017; 10():171-177. PubMed ID: 28546761
[TBL] [Abstract][Full Text] [Related]
17. Multicenter Retrospective Andalusian Study of the Use of Sonidegib for the Treatment of Local Advanced Basal Cell Carcinoma in Real Clinical Practice.
Ruiz-Villaverde R; Herrera-Acosta E; Ruiz de Casas A; Villegas-Romero IM; Moreno-Suárez FG; Vílchez-Márquez F; Galán-Gutiérrez M; Vázquez-Bayo MC; Cases-Mérida S; Almazán-Fernández FM
J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685698
[TBL] [Abstract][Full Text] [Related]
18. A multicenter real-world analysis of risk factors, therapeutics, and outcomes of patients with metastatic basal cell carcinoma.
Groover M; Gupta N; Granger E; Forrester VJ; Anstadt EJ; Su W; Heusinkveld L; Chen A; Lukens JN; Silk AW; Vidimos AT; Schoenfeld JD; Koyfman SA; Ruiz ES
J Am Acad Dermatol; 2024 Mar; 90(3):545-551. PubMed ID: 37949119
[TBL] [Abstract][Full Text] [Related]
19. Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib.
Martins PC; Filipe RV; Barbosa R; Julião I; Azevedo R; Ribeiro M; de Sousa A
Autops Case Rep; 2019; 9(4):e2019116. PubMed ID: 31641658
[TBL] [Abstract][Full Text] [Related]
20. New therapeutic developments for basal cell carcinoma.
Kunstfeld R; Nguyen VA
J Dtsch Dermatol Ges; 2023 Apr; 21(4):382-385. PubMed ID: 37070499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
